Issue Date: August 6, 2012
Cleveland BioLabs Inks Pact With Russia
Cleveland BioLabs has signed a $4 million agreement with the Russian Ministry of Industry & Trade for CBLB612, a drug in development for stimulation of hematopoietic stem cell proliferation and mobilization. The contract, issued under Russia’s Pharma 2020 initiative, provides funding over a three-year period to support research through Phase II clinical trials. Cleveland BioLabs says CBLB612 is a candidate for use in bone marrow transplants.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society